Five years after the launch of the GENESIS project, supported by France 2030, URGO and its consortium partners — CNRS, Lyon 1 University, CECS, the French Blood Establishment (EFS) and Dassault Systèmes — have announced a world first: the creation of living artificial skin in the laboratory, cryopreserved and designed to be ready for grafting onto patients.
This entirely French breakthrough paves the way for a clinical study involving the first patients, expected in 2030, and for industrial scale-up.
Today, the treatment of severe wounds, particularly in major burn victims, requires harvesting healthy skin, repeated surgical procedures and lengthy hospital stays.
In the future, GENESIS could enable wounds to be closed without harvesting skin from patients, transforming their treatment and reducing the suffering associated with care.
A breakthrough offering hope to patients
Severe wounds, such as those sustained by major burn victims, can have a lasting impact on patients’ lives and those of their loved ones. In addition to the trauma of the accident, patients face a particularly demanding treatment journey involving pain, repeated surgical procedures, the risk of infection and often prolonged hospitalisation.
When injuries cover a large area of the body, the amount of healthy skin available for autologous grafting may be insufficient. Medical teams must therefore adapt their harvesting procedures and perform repeated operations to gradually cover the burned areas.
GENESIS aims to make artificial skin available to healthcare professionals, produced in advance, cryopreserved and ready for immediate use in the operating theatre. The goal is to replace autologous skin grafts, enabling wounds to be closed immediately without harvesting healthy skin from the patient.
For patients, this innovation could mean fewer operations, less burdensome treatment and shorter hospital stays. It could also reduce the burden of follow-up care and lower treatment costs.
A world first combining several technological breakthroughs
The skin is the body’s largest organ and performs essential functions. It protects the body against external threats, limits water loss and withstands the mechanical stresses caused by movement. Severe wounds compromise these functions and expose patients to significant complications. Artificial skin will aim to restore this protective barrier.
For the first time worldwide, a single artificial skin product combines three major advances:
1. An unlimited supply of living cells. URGO is now among the approximately ten companies worldwide to have its own pharmaceutical-grade cell bank.
2. Skin that closely resembles natural skin. The cells are assembled in the correct sequence and organised in three dimensions. The result is functional skin, sufficiently robust to be handled by a surgeon and grafted onto a patient.
3. Skin ready for grafting. Thanks to cryopreservation, the skin can be produced in advance, frozen, stored and shipped to hospitals worldwide. Following thawing, its cells remain alive and functional.
Five years ago, we set ourselves an ambitious challenge: to recreate skin. Today, our teams and partners have achieved this world first. Tomorrow, it could bring hope to patients with severe wounds, offering less burdensome treatment and faster healing. This project perfectly embodies URGO’s mission to support patients and healthcare professionals.
Guirec Le Lous, President of the URGO Group
Led by URGO, GENESIS brings together:
- The French Blood Establishment (EFS), through its CDMO activities
- CECS – I-Stem laboratory
- CNRS and Lyon 1 University, through the Laboratory of Tissue Biology and Therapeutic Engineering, which they jointly oversee
- Dassault Systèmes
Together, these partners combine expertise in biology, tissue repair, biomanufacturing and digital twins of biological processes.
Based in the Dijon metropolitan area, with a dedicated research laboratory inaugurated in 2022, the GENESIS project also benefits from support from the State’s regional authorities, the Bourgogne-Franche-Comté Region and Dijon Métropole.
When the project was launched in 2021, it received €22.8 million in government funding under the Future Investment Programme, administered by Bpifrance.
First clinical study expected in 2030
GENESIS is built around three challenges: technological, clinical and industrial.
With this milestone, URGO has achieved its technological objective and completed the research phase dedicated to designing the artificial skin. The project is now entering a development phase focused on preparing the first clinical trial, expected to begin as early as 2030, using the EFS’s pharmaceutical manufacturing facilities, as well as scaling up production for commercialisation targeted for 2040.






